A Credibility Assessment Plan for an In Silico Model that Predicts the Dose–Response Relationship of New Tuberculosis Treatments-Reference-Cited by-同舟云学术

A Credibility Assessment Plan for an In Silico Model that Predicts the Dose–Response Relationship of New Tuberculosis Treatments

Published:2022-09-17 Issue:1 Volume:51 Page:200-210
ISSN:0090-6964
Container-title:Annals of Biomedical Engineering
language:en
Short-container-title:Ann Biomed Eng

Author:

Curreli Cristina^ORCID,Di Salvatore Valentina^ORCID,Russo Giulia^ORCID,Pappalardo Francesco^ORCID,Viceconti Marco^ORCID

Abstract

AbstractTuberculosis is one of the leading causes of death in several developing countries and a public health emergency of international concern. In Silico Trials can be used to support innovation in the context of drug development reducing the duration and the cost of the clinical experimentations, a particularly desirable goal for diseases such as tuberculosis. The agent-based Universal Immune System Simulator was used to develop an In Silico Trials environment that can predict the dose–response of new therapeutic vaccines against pulmonary tuberculosis, supporting the optimal design of clinical trials. But before such in silico methodology can be used in the evaluation of new treatments, it is mandatory to assess the credibility of this predictive model. This study presents a risk-informed credibility assessment plan inspired by the ASME V&V 40‐2018 technical standard. Based on the selected context of use and regulatory impact of the technology, a detailed risk analysis is described together with the definition of all the verification and validation activities and related acceptability criteria. The work provides an example of the first steps required for the regulatory evaluation of an agent-based model used in the context of drug development.

Funder

Horizon 2020 Framework Programme

Alma Mater Studiorum - Università di Bologna

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering

Link

https://link.springer.com/content/pdf/10.1007/s10439-022-03078-w.pdf

Reference43 articles.

1. Archivel Farma S.L. Double-Blind, Randomized, Placebo-Controlled, Phase IIb Clinical Trial to Investigate the Efficacy of RUTI® Therapeutic Vaccination as Adjuvant of Tuberculosis Chemotherapy, clinicaltrials.gov, Clinical trial registration NCT04919239, Mar. 2022.]; https://clinicaltrials.gov/ct2/show/NCT04919239.

2. ASME, V&V 40—2018: Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices, 2018.

3. Boaz, M. J., et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin. Vaccine Immunol. 16(2):147–155, 2009. https://doi.org/10.1128/CVI.00326-08.

4. Boonpeng, A., S. Jaruratanasirikul, T. Wattanavijitkul, M. Nawakitrangsan, and M. Samaeng. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. Biopharm. Drug Dispos. 42(7):329–337, 2021. https://doi.org/10.1002/bdd.2294.

5. C. for D. and R. Health, Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions, U.S. Food and Drug Administration, Dec. 22, 2021; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Computational systems immunovirology;Frontiers in Immunology;2023-07-05

2. Serverless Approach to Sensitivity Analysis of Computational Models;2023 IEEE/ACM 23rd International Symposium on Cluster, Cloud and Internet Computing (CCGrid);2023-05